 Connection
Paul Bunn to Carboplatin
This is a "connection" page, showing publications Paul Bunn has written about Carboplatin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.495 |
|
|
|
-
Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 05; 20(3):148-160.e2.
Score: 0.654
-
Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6317-23.
Score: 0.321
-
Bunn PA. Platinums in lung cancer: sufficient or necessary? J Clin Oncol. 2005 May 01; 23(13):2882-3.
Score: 0.250
-
Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg. 2000 Mar; 119(3):429-39.
Score: 0.177
-
Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1998 Feb 01; 40(3):559-67.
Score: 0.153
-
Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997 Jul; 3(7):1117-23.
Score: 0.147
-
Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Aug; 22(4 Suppl 9):2-6.
Score: 0.129
-
Bunn PA. Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol. 1992 Feb; 19(1 Suppl 2):1-11.
Score: 0.101
-
Bunn PA. Diseases desperate grown. J Natl Cancer Inst. 2008 Apr 16; 100(8):520-1.
Score: 0.078
-
Bunn PA. Early-stage NSCLC: the role of radiotherapy and systemic therapy. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S31-40.
Score: 0.061
-
Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):341-3.
Score: 0.055
-
Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
Score: 0.052
-
Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9.
Score: 0.046
-
Bunn PA. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):25-30.
Score: 0.041
-
Bunn PA. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-153-S12-162.
Score: 0.037
-
Bunn PA. Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):9-15.
Score: 0.035
-
Bunn PA. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):18-25.
Score: 0.035
-
Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge R, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10; 29(26):3567-73.
Score: 0.024
-
Pisters KM, Valli?res E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9.
Score: 0.022
-
Bunn PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989 Apr; 16(2 Suppl 5):27-33.
Score: 0.021
-
Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May; 24(3):213-21.
Score: 0.017
-
Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
Score: 0.016
-
Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8.
Score: 0.012
-
Pisters KM, Kris MG, Bunn PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-41-S12-44.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|